Category - Markets

Markets

Roth starts Seelos Therapeutics at buy; PT $8

Roth Capital partners launched coverage of Seelos Therapeutics (NASDAQ:SEEL) with a “buy” rating and $8 price target. The stock closed at $2.71 on May 13.

May 14, 2019

Markets

BTIG starts MannKind at buy; PT $3

BTIG initiated coverage of MannKind (NASDAQ:MNKD) with a “buy” rating and price target of $3. The stock closed at $1.23 on May 13.

May 14, 2019

Markets

Alliance Global starts Canopy Growth at buy; PT $75 (Canadian)

Alliance Global Partners launched coverage of Canopy Growth (TSX:WEED; NYSE:CGC) with a “buy” rating and $75 price target. The stock closed at $63.78 on May 10.

May 13, 2019

Markets

SVB Leerink starts Turning Point Therapeutics at OP; PT $42

SVB Leerink launched coverage of Turning Point Therapeutics (NASDAQ:TPTX) with an “outperform” rating and $42 price target. The stock closed at $32.12 on May 10.

May 13, 2019

Markets

SVB Leerink starts Hookipa Pharma at OP; PT $20

SVB Leerink initiated coverage of Hookipa Pharma (NASDAQ:HOOK) with an “outperform” rating and $20 price target. The stock closed at $13.85 on May 10.

May 13, 2019

Markets

Canaccord ups ShockWave Medical PT to $50 from $39

Canaccord Genuity raised its price target for ShockWave Medical (NASDAQ:SWAV) to $50 from $39 after the company’s first quarter results beat consensus estimates.

May 9, 2019

Markets

Stifel ups Protagonist Therapeutics to buy; PT up to $17 from $11

Stifel upgraded Protagonist Therapeutics (NASDAQ:PTGX) to “buy” from “neutral” and raised its price target to $17 from $11 after expansion of a deal with Janssen for PTG-200 and other IL-23 receptor antagonists. The...

May 9, 2019

Markets

Canaccord cuts OraSure to hold; PT down to $10 from $16

Canaccord Genuity downgraded OraSure Technologies (NASDAQ:OSUR) to “hold” from “buy” and dropped its price target to $10 from $16, citing disappointment of underlying trends in direct-to-consumer (DTC) genetic testing...

May 9, 2019

Markets

HCW adjusts ReWalk Robotics PT to $4

H.C. Wainwright adjusted its price target for ReWalk Robotics (NASDAQ:RWLK) to $4 from 25 cents, citing a potential mid-2019 launch of the company’s ReStoresoft exosuit for rehabilitation of stroke patients in U.S. and...

May 8, 2019

Markets

ContraVir Pharma receives positive NASDAQ listing decision

The Nasdaq Hearings Panel granted ContraVir Pharmaceuticals’ (NASDAQ:CTRV) request for continued listing on The Nasdaq Capital Market, subject to compliance with certain conditions.

May 6, 2019

Category - Markets

Subscribe